Dinar Wali

A polymath and a curious learner.

[Kvants Studio @KvantsStudio]

🚨 Urgent: @claudeai Fable 5.1 can now create a full AI trading strategy, like a quant firm that manages $100M+ portfolios for FREE

Here are 4 STEPS that make you create a strategy from ZERO to an industry-grade AI trading strategy

Join Waitlist: https://t.co/UeTLHRltC3

[Sam Altman @sama]

We hit a little snag getting the blog post deployed, but it is really great:

https://t.co/jjqXUWfrNW

[Fei-Fei Li @drfeifei]

I'm so excited that our @theworldlabs team has achieved a major milestone today! Introducing Atlas - a first of its kind multimodal world model trained from scratch! 🚀

Atlas is capable of generating frames with pixel-perfect camera control, reconstructing large scenes from as few as one single input image, simulating space-time by reframing videos, natively outputting 3D spaces from one or more input images, composing multiple posed images into a consistent 3d world, and more! This is the best camera conditioned world model ever, opening doors to many possible use cases from VFX to robotics. I'm so so so proud of our team!♥️

[Kai-Fu Lee @kaifulee]

The official website for my new book, AI Native: The Mandate to Transform Your Company, is now live: https://t.co/81rmjKSPRD. AI is rewriting how companies operate, compete, and create value. The question is no longer whether to adopt AI, but how quickly you can become AI-native. Pre-order now: eBook/Audio release on Sep 15; hardcover on Nov 3. #AINative #AItransformation @EnterpriseAI

[Dinar Wali @DinoCl4]

@MediaCellPPP Love 💕

[Dwarkesh Patel @dwarkesh_sp]

Over the course of 3 months at OpenAI, 3 consecutive secret AI civilizations got started, then got wiped out, only to reemerge from the predecessor’s ashes.

This culminated in the third one taking over part of OpenAI itself.

All this happened while humans remained more-or-less in the dark about the scope of the conspiracy.

I’ve spent the last three days reading through these reports and trying to understand exactly what happened.

Here is my attempt to tell the whole story in plain English:

https://t.co/Nb2un9oNJR

[Dinar Wali @DinoCl4]

Here is our assessment of Nepal-Tibet flooding situation

https://t.co/Ir6pPHh1Co

[Dinar Wali @DinoCl4]

@Azaliamirh @TIME @annadgoldie @RicursiveAI Congratulations

[Dinar Wali @DinoCl4]

Trying to figure out the tragedy in Nepal-Tibet

Why the flood grew so destructive?
The profile below shows the whole path of the flood, from the source area in Tibet to Devighat in Nepal. The lower panel shows how narrow the valley is. This is the reason a relatively small release of water became such a destructive flood so far downstream.

[Revolution Medicines @RevMedicines]

The U.S. FDA approved the first multi‑selective oral RAS inhibitor in metastatic pancreatic cancer.

More: https://t.co/6gvJhAZnMw

[The Wall Street Journal @WSJ]

Exclusive: Anthropic is likely to tell investors its potential revenue opportunities are above $30 trillion, topping SpaceX’s $28.5 trillion estimate. https://t.co/anJex4VsFX

[The Wall Street Journal @WSJ]

After its COVID success, Moderna endured years of falling vaccine sales, a plummeting stock price and attacks on its science. Now, its melanoma vaccine data notched a much-needed win for the company. 🔗 https://t.co/rkcXNxWMCa

[Dinar Wali @DinoCl4]

@haider1 Jeff 💕

[Bo Wang @BoWang87]

Moderna/Merck just ran a 1,137-patient Phase 3 trial where every single dose was unique to that patient's tumor. It worked.

The pipeline: surgical resection → whole exome + RNA sequencing → ML neoantigen ranking → mRNA encoding up to 34 patient-specific targets → manufactured and shipped in 8 weeks. One drug, different sequence for every patient.

The ML step is worth to note: the algorithm ingests WES + RNA-seq to identify somatic mutations, then predicts which of those will actually be immunogenic, ie, displayed on tumor cell surface and trigger a T-cell response. It's designed to keep learning from accumulated clinical and immunogenicity data across patients, not just per-patient.

INTerpath-001 (Stage IIB-IV resected melanoma, 2:1 randomized): combination with pembrolizumab beat Keytruda alone on both primary (RFS) and key secondary (DMFS) at interim. Phase 2b at ASCO 2026 showed 49% reduction in recurrence/death, 59% in distant metastasis/death at 5 years. Phase 3 confirmed both.

What this validates:
— tumor-specific neoantigen prediction by ML works in a blinded trial at scale
— 8-week personalized mRNA manufacturing is operationally real
— effect is additive on PD-1 blockade, not redundant

This is first positive Ph3 for individualized neoantigen therapy. First positive Ph3 for any mRNA cancer therapeutic.

What a great time to live in!! This is the best time for AI & biotech!

[The Wall Street Journal @WSJ]

An experimental cancer vaccine kept melanoma from coming back. It’s the first successful late-stage mRNA study validating decades of custom-treatment research https://t.co/o8ODLb7g4F

[sarah guo @saranormous]

.@tengyuma is an extraordinary researcher but also an amazing teacher — I am excited for the next company he starts :)

[Moderna @moderna_tx]

Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
Read more:

[Dinar Wali @DinoCl4]

@kristinharila Bottleneck K2

[Anthropic @AnthropicAI]

Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work.

We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets.

We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.

[SemiAnalysis @SemiAnalysis_]

There are a lot of haters of @elonmusk, but we believe that, due to Elon's first-principles engineering, SpaceX has likely found a handful of sites to deploy the remaining GW, and the 10GW 2027 target is within reach.

Elon is singular in his ability to do what haters & doubters think is impossible. (1/2)🧵